Andrew Roberts

Andrew Roberts led the clinical development of venetoclax, the first BCL-2 selective inhibitor approved for cancer treatment. His translational research bridged decades of BCL-2 biology to the landmark CLL clinical trials that established venetoclax as a standard of care. He demonstrated venetoclax efficacy in AML and multiple myeloma, expanding BH3-mimetic therapy across hematologic malignancies. His work exemplifies the successful translation of cancer cell death biology into approved therapy.